Abstract:Introduction: Cardiovascular diseases have been the leading causes of death all over the world for decades. Vascular smooth muscle cells (VSMCs) form a major section of a blood vessel, conferring structural and physiological support to withstand any change under physiological or pathological conditions. VSMC phenotypic modulation from a contractile phenotype to a synthetic state is pivotal for the development of several vascular diseases such as neointima formation after angioplasty and atherosclerosis. Decreased expression of VSMC differentiation markers including SM ɑ-actin (Acta2), SM-myosin heavy chain (Myh11) and SM22 alpha (Tagln) indicates VSMC phenotypic switching, which is accompanied by increasing VSMC proliferation, migration and synthesis of metalloproteinase[1]. However, the molecular mechanisms that underlie VSMC phenotypic switching remain largely unknown. SMYD2, a SET and MYND domain-containing protein, belongs to the SMYD family of protein lysine methyltransferases. Structurally, SET domain regulates lysine methylation of target proteins (as involved in transcription, cell differentiation and cell proliferation), while zinc finger motif MYND domain may interact with proline rich regions and facilitate protein-protein interaction. SMYD2 was originally reported to methylate histone 3 at lysine 4 (H3K4) and lysine 36 (H3K36) and H4 at lysine 20 (H4K20), and plays an essential role in HIV-1 latency and cardiac development [2-3]. Some studies found that SMYD2 can also methylate non-histone proteins such as p53, Hsp90, and Rb and regulate their functions [4-6]. Interestingly, SMYD2 has recently been implicated in human patients with abdominal aortic aneurysm in GWAS screening [7]. The aim of this study is to investigate the role of SMYD2 in the control of VSMC phenotypic switching and neointima formation. Methods: We used Western blotting and PCR to assess SMYD2 expression and VSMC marker gene expression in VSMC phenotypic change in vitro and murine carotid ligation injury model in vivo. In the ligation injury model, right common carotid artery (CCA) was ligated and harvested after 7, 14, and 28 days. SMYD2smc-/- (SMYD2 conditional knockout in VSMCs) mice and SMYD2flox/flox (SMYD2 flox control) mice were subjected to ligation model and CCA was obtained for histological evaluation after7 days, 14 days and 28days. Primary VSMCs were isolated from SMYD2smc-/- mice and SMYD2flox/flox mice and then VSMC marker gene expression was examined by Western blotting and PCR. Furthermore, we also checked expression of SMYD2 in murine atherosclerosis which is closely related to VSMC phenotypic change. Results: The expression of SMYD2 significantly decreased in response to platelet-derived growth factor BB (PDGF-BB) in the serum-starved VSMCs. In the in vivo model, we found that SMYD2 expression was also reduced in the injured versus sham-operated carotid arteries. In comparison with normal healthy arteries, atherosclerotic arteries have a substantially decreased SMYD2 expression in mouse vascular tissues. Moreover, SMYD2 ablation in VSMCs significantly exacerbated ligation injury-induced neointima formation in mice and drastically inhibited VSMC marker gene expression. Conclusion: Our findings demonstrated that SMYD2 down-regulation in VSMCs promotes VSMC phenotypic changing and neointima formation after injury, suggesting that SMYD2 may function as a novel inhibitor of vascular remodeling associated with physical injury and atherosclerotic disease. Disclosure: Nothing to disclose

SMYD1 modulates the proliferation of multipotent cardiac progenitor cells derived from human pluripotent stem cells during myocardial differentiation through GSK3β/β-catenin&ERK signaling

Inhibition of HSC70 Alleviates Hypertrophic Cardiomyopathy Pathology in Human Induced Pluripotent Stem Cell‐derived Cardiomyocytes with a MYBPC3 Mutation

Abstract We033: Heart-Specific Histone Methyltransferase SMYD1 Promotes Cardiac Maturation in the Direct Conversion of Human Fibroblasts into Cardiomyocytes.

Smyd1 Orchestrates Early Heart Development Through Positive and Negative Gene Regulation

The Role Of Histone Methyltransferase Smyd4 In Cardioprogenitor Cell Specification And Differentiation

Smyd1, The Myogenic Activator, Is A Direct Target Of Serum Response Factor And Myogenin

SMYD1a protects the heart from ischemic injury by regulating OPA1-mediated cristae remodeling and supercomplex formation

CHD4 and SMYD1 repress common transcriptional programs in the developing heart

The Roles of SMYD4 in Epigenetic Regulation of Cardiac Development in Zebrafish

Pioneering function of Isl1 in the epigenetic control of cardiomyocyte cell fate.

Histone methyltransferase Smyd1 regulates mitochondrial energetics in the heart

MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways

Tudor-SN promotes cardiomyocyte proliferation and neonatal heart regeneration through regulating the phosphorylation of YAP

Myocardial Smad4 is Essential for Cardiogenesis in Mouse Embryos

SMYD1-mediated Mono-Methylation of Lysine K35 of the sarcomeric Myosin Heavy Chain (MHC) is fundamental for thick filament assembly in zebrafish and human iPSC-derived cardiomyocytes

Set and MYND Domain-containing Protein 2 (SMYD2) is a Critical Regulator for Vascular Smooth Muscle Cell Phenotypic Switching and Neointima Formation

Deciphering the role of SMARCA4 in cardiac disorders: Insights from single-cell studies on dilated cardiomyopathy and coronary heart disease

Effects of CMYA1 overexpression on cardiac structure and function in mice

A De Novo Mutation of SMYD1 (p.f272l) is Responsible for Hypertrophic Cardiomyopathy in a Chinese Patient.

Targeting Mll1 H3K4 Methyltransferase Activity to Guide Cardiac Lineage Specific Reprogramming of Fibroblasts

O186 Nucleosome Assembly Protein 1-Like 1 Knockdown Promotes Cardiomyocytes Differentiation by Notch Signaling in Mouse Induced Pluripotent Stem Cells